Notable Recent Publications

These are some recent publications which give a flavour of the research from the Barclay lab. For a complete list of publications, please see below.


Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature (2016).
Jason S. Long, Efstathios S. Giotis, Olivier Moncorgé, Rebecca Frise, Bhakti Mistry, Joe James, Mireille Morisson, Munir Iqbal, Alain Vignal, Michael A. Skinner & Wendy S. Barclay

This paper identified a key factor that explained why the polymerases from avian influenza viruses are restricted in humans.  For more, please see the associated New and Views.

See our latest ANP32 papers here: eLIFE, Journal of Virology, Journal of Virology.


The mechanism of resistance to favipiravir in influenza. PNAS (2018).
Daniel H. GoldhillAartjan J. W. te VelthuisRobert A. FletcherPinky LangatMaria ZambonAngie Lackenby & Wendy S. Barclay

This paper showed how influenza could evolve resistance to favipiravir, an antiviral that may be used to treat influenza. The residue that mutated to give resistance was highly conserved suggesting that the mechanism of resistance may be applicable to other RNA viruses.


Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. Plos Path. (2018).
Hui Li*, Konrad C. Bradley*, Jason S. Long, Rebecca Frise, Jonathan W. Ashcroft, Lorian C. Hartgroves, Holly Shelton, Spyridon Makris, Cecilia Johansson, Bin Cao & Wendy S. Barclay

Why do avian influenza viruses like H5N1 cause such severe disease in humans? This paper demonstrated that H5N1 viruses replicate better than human viruses in myeloid cells from mice leading to a cytokine storm and more severe disease.


Citation

BibTex format

@article{McKay:2020:10.1038/s41467-020-17409-9,
author = {McKay, PF and Hu, K and Blakney, AK and Samnuan, K and Brown, JC and Penn, R and Zhou, J and Bouton, CR and Rogers, P and Polra, K and Lin, PJC and Barbosa, C and Tam, YK and Barclay, WS and Shattock, RJ},
doi = {10.1038/s41467-020-17409-9},
journal = {Nature Communications},
pages = {1--7},
title = {Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice},
url = {http://dx.doi.org/10.1038/s41467-020-17409-9},
volume = {11},
year = {2020}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle (LNP) as a vaccine. We observe remarkably high and dose-dependent SARS-CoV-2 specific antibody titers in mouse sera, as well as robust neutralization of both a pseudo-virus and wild-type virus. Upon further characterization we find that the neutralization is proportional to the quantity of specific IgG and of higher magnitude than recovered COVID-19 patients. saRNA LNP immunizations induce a Th1-biased response in mice, and there is no antibody-dependent enhancement (ADE) observed. Finally, we observe high cellular responses, as characterized by IFN-γ production, upon re-stimulation with SARS-CoV-2 peptides. These data provide insight into the vaccine design and evaluation of immunogenicity to enable rapid translation to the clinic.
AU - McKay,PF
AU - Hu,K
AU - Blakney,AK
AU - Samnuan,K
AU - Brown,JC
AU - Penn,R
AU - Zhou,J
AU - Bouton,CR
AU - Rogers,P
AU - Polra,K
AU - Lin,PJC
AU - Barbosa,C
AU - Tam,YK
AU - Barclay,WS
AU - Shattock,RJ
DO - 10.1038/s41467-020-17409-9
EP - 7
PY - 2020///
SN - 2041-1723
SP - 1
TI - Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
T2 - Nature Communications
UR - http://dx.doi.org/10.1038/s41467-020-17409-9
UR - https://www.ncbi.nlm.nih.gov/pubmed/32647131
UR - https://www.nature.com/articles/s41467-020-17409-9
UR - http://hdl.handle.net/10044/1/80898
VL - 11
ER -